SEC Form 4 · accession 0001104659-16-140287
Vitae Pharmaceuticals, Inc · VTAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Gregg
Officer — Chief Science Officer
Period of report
Aug 15, 2016
Accepted (ET)
Aug 17, 2016 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001157602
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 29, 2016 | A | 2,100 | $6.11 | A | 104,372 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $8.79 | Aug 15, 2016 | A | 16,500 | A | — | Aug 14, 2026 | Common Stock | 16,500 | 16,500 | D |
Explanation of responses
- F1The Reporting Person acquired 2,100 shares of Common Stock pursuant to the Vitae Pharmaceuticals, Inc. 2014 Employee Stock Purchase Plan.
- F2This option shall vest with respect to 25% of the shares of stock which are subject to this option on August 15, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date.